10,385 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Headlands Technologies LLC

Headlands Technologies LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,385 shares of the company's stock, valued at approximately $893,000.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Charles Schwab Investment Management Inc. lifted its holdings in Novo Nordisk A/S by 16.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 204,583 shares of the company's stock valued at $24,360,000 after purchasing an additional 28,988 shares in the last quarter. Benjamin Edwards Inc. raised its holdings in shares of Novo Nordisk A/S by 643.8% during the third quarter. Benjamin Edwards Inc. now owns 25,697 shares of the company's stock valued at $3,060,000 after acquiring an additional 22,242 shares during the last quarter. Hilltop Holdings Inc. lifted its position in shares of Novo Nordisk A/S by 103.3% in the third quarter. Hilltop Holdings Inc. now owns 7,978 shares of the company's stock valued at $950,000 after acquiring an additional 4,054 shares in the last quarter. Integrated Wealth Concepts LLC boosted its stake in shares of Novo Nordisk A/S by 1.5% in the third quarter. Integrated Wealth Concepts LLC now owns 33,027 shares of the company's stock worth $3,933,000 after acquiring an additional 477 shares during the last quarter. Finally, IHT Wealth Management LLC increased its position in shares of Novo Nordisk A/S by 39.9% during the third quarter. IHT Wealth Management LLC now owns 11,311 shares of the company's stock worth $1,343,000 after purchasing an additional 3,228 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on NVO. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Trading Down 1.7 %

Shares of NYSE NVO traded down $1.16 during trading on Thursday, reaching $67.08. The stock had a trading volume of 8,818,417 shares, compared to its average volume of 5,614,006. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market cap of $301.04 billion, a P/E ratio of 20.39, a PEG ratio of 0.90 and a beta of 0.42. The business's 50-day moving average price is $81.36 and its 200-day moving average price is $97.26. Novo Nordisk A/S has a fifty-two week low of $66.88 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.